Skip to main content
TipRanks
Go Ultimate75% OFF

BIOTON S.A. (7U5) AI Stock Analysis

0 Followers
DE:7U5

BIOTON S.A.

(Frankfurt:7U5)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Low LeverageA conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.
Negative Factors
Low Operating Cash FlowLow operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.

BIOTON S.A. (7U5) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:7U5-20.13%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 67.01M
Dividend Yield
―
Average Volume (3M)
2,800
Price to Earnings (P/E)
-25.0
Beta (1Y)
0.31
Revenue Growth
-15.76%
EPS Growth
-305.13%
Country
Germany
Employees
361
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

BIOTON S.A. Business Overview & Revenue Model

Company Description

Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on di...

BIOTON S.A. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7U5 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PL:MABPL:MAB41NeutralPLN 166.80M-2.95-124.37%―56.67%12.68%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%DE:7U5PL:MQRPL:SVEPL:MOCPL:MABPL:NNGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7U5 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7U5BIOTON S.A.0.74-0.22-22.96%
PL:MQRPure Biologics SA1.38-3.67-72.62%
PL:SVEBiomed-Lublin Wytwornia Surowic i Szczepionek S.A.2.84-1.17-29.09%
PL:MOCOncoArendi Therapeutics SA5.53-0.46-7.68%
PL:MABMabion SA10.322.7436.15%
PL:NNGNanoGroup SA2.06-0.63-23.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.